Improved Real-World Outcomes

Eversense Is Putting Glycemic Goals Within Reach

Long-Term Wear

Industry leading adherence

>23 hours wear time^1-3

Learn More

Acting on continuous insights

Exceptional real-world time in target

59%-69% time in target⁴

Learn More

Improved self-management

HbA1C reduction across multiple pivotal studies^1-3

0.5% HbA1C reduction²

Learn More

What is Long Term CGM?

Longer wear time

92% industry-leading adherence across 3 pivotal trials.^1,2,3

Fully implantable 180-day sensor.

Continuous readings and alerts around the clock.

Greater insight

Exceptional accuracy, especially in the 2.2-3.3 mmol/L range.⁴

Charts, graphs and in-app reports to improve glycemic awareness.

Three types of alerts (audio, on body vibe and mobile text) to guide safe management.
Fewer obstacles

No twice-monthly sensor replacement.

Near-real time feedback to help predict and monitor trends.

Detects 95% of hyper/hypo events in 15 minutes.⁵

Improved self-management

Exceptional 59-69% real-world time in target.¹

Demonstrated eHbA1c of 6.9%¹, below recognized treatment targets.⁶

Improved control reduces health risks and complications.⁷

Accuracy and Discretion for your Members

The Eversense long-term CGM System uniquely balances accuracy and discretion with an exceptional user experience.

1 Christiansen MP. PRECISION. Diabetes Technology & Therapeutics. Volume 21, Number 5, 2019. 2 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 3 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68.= 4 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.

MKT-001309 Rev1

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.